What is Trially?
Trially operates as an AI-native platform specifically engineered to streamline the complex process of patient matching and enrollment in clinical trials. By utilizing sophisticated algorithms, the company significantly reduces the time and administrative burden associated with prescreening and site-level recruitment. The platform serves a diverse ecosystem of stakeholders, including clinical research sites, pharmaceutical sponsors, and physicians, providing a secure and compliant environment for data-driven decision-making.
In a market where patient recruitment remains a primary cause of trial delays and increased costs, Trially distinguishes itself by minimizing screen failures and enhancing the accuracy of candidate identification. Its technology-first approach allows for more efficient trial execution, ultimately accelerating the path to market for life-saving therapies.
How much funding has Trially raised?
Trially has raised a total of $4.7M across 1 funding round:
Seed
$4.7M
Seed (2025): $4.7M with participation from Alpaca, Gaingels, Redbud Brands, Blu Ventures, The Council, Atria, Flyover Capital, and Looking Glass Capital
Key Investors in Trially
Alpaca
Alpaca VC is a venture capital firm that specializes in investing in real estate and commerce startups at the intersection of the physical and digital world, providing deep expertise in deal structuring and growth support.
Gaingels
Gaingels is a leading investment syndicate representing the LGBTQ community and allies, known for deploying significant capital into high-growth companies across various sectors including healthcare and technology.
Flyover Capital
Flyover Capital is an investment firm focused on supporting underestimated technology leaders in the Flyover region of the United States, emphasizing early-stage funding and long-term strategic growth.
What's next for Trially?
With the successful closure of this funding round, Trially is expected to prioritize the expansion of its technical infrastructure and the broadening of its market reach. The company's strategic roadmap likely includes deepening its integration with existing clinical research management systems and enhancing its AI capabilities to handle more complex trial protocols. As the firm transitions from its current development phase toward broader commercial adoption, the focus will remain on maintaining high standards of data compliance while scaling its enrollment efficiency metrics. Investors are closely watching how Trially will leverage its recent capital to solidify its position as a critical utility in the global clinical research infrastructure.
See full Trially company page
